Trial Profile
A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms LEAD
- Sponsors Ipsen
- 23 Mar 2021 Results of post-hoc analysis of two studies PRIMARYS5 (NCT00690898) and LEAD6 (NCT00701363) assessing most common oral medications used by patients with acromegaly during treatment with lanreotide autogel 120 mg , presented at the 103rd Annual Meeting of the Endocrine Society.
- 19 Nov 2015 New trial record